Navigation Links
Volcano Sponsors First Study Designed to Determine if IVUS Can Identify Patients at Risk for Stent Thrombosis and to Demonstrate the Benefit of IVUS Guidance for Procedural Outcome

3,000 Patient Multi-center IVUS Sub-study Part of the Cardiovascular Research Foundation's ADAPT-DES Study to Quantify Causes and Cures of Drug

Eluting Stent Thrombosis

SAN DIEGO, Oct. 22 /PRNewswire-FirstCall/ -- Volcano Corporation (Nasdaq: VOLC) [TCT Booth #2013 Level 2], a leading manufacturer of intravascular ultrasound (IVUS) and functional measurement (FM) technology, announced today its sponsorship of the first major study designed to examine the role of IVUS in ensuring accurate stent placement. The 3,000 patient IVUS sub-study is part of the Cardiovascular Research Foundation's (CRF) ADAPT-DES study (Assessment of Dual AntiPlatelet Therapy with Drug-Eluting Stents), a prospective, multi-center registry of 11,000 (and up to 15,000) patients with coronary artery disease undergoing stent-assisted percutaneous coronary intervention (PCI) using drug-eluting stents (DES). The study's main objectives are to determine the frequency, timing and correlates (clinical, angiographic and IVUS) of DES thrombosis and the relationship of aspirin and/or clopidogrel hyporesponsiveness, and general platelet reactivity to early and late DES thrombosis.

"Although the benefits of IVUS have been anecdotally discussed by many interventional cardiologists and quantified in a number of published studies, the additive value of IVUS measures as independent predictors of stent thrombosis beyond the information present from clinical and angiographic variables has not been assessed in a prospective, multi-center registry," commented Gregg W. Stone, MD, Principal Investigator of ADAPT-DES and Chairman of the Cardiovascular Research Foundation. "The ADAPT-DES IVUS sub-study is expected to provide definitive evidence as to whether IVUS can identify patients at heightened risk for stent thrombosis."

The IVUS sub-study is expected to confirm the collaborative work of Dr. Antonio Colombo and his associates who identified IVUS parameters as independent predictors of stent thrombosis. In his findings, Dr. Colombo has demonstrated a high rate of IVUS-detected stent under-expansion and incomplete stent apposition (ISA) when bare-metal stents (BMS) have been implanted via angiographic guidance alone. Additionally, similar findings regarding stent under-expansion and residual edge stenoses have been discussed in numerous retrospective reports published since 2002 regarding acute and sub-acute BMS and DES thrombosis. Volcano's Eagle Eye(R) Gold IVUS catheters will be used in all sub-study patients at the initiation of the sub-study and in follow-up assessments. Analysis will include assessment of lesion morphology by using both traditional grayscale IVUS and Volcano's proprietary VH(TM) IVUS tissue characterization technology.

"The S.T.L.L.R. study* by Costa, et al, has shown that geographic miss is a contributing factor to poor stenting outcomes and stent thrombosis. We expect that the ADAPT-DES IVUS sub-study will confirm what many interventionalists already intuitively know-- that accurate stent placement really can reduce stent thrombosis and that IVUS is an effective, efficient way to optimize stent results," said Scott Huennekens, President & CEO, Volcano Corporation. "Volcano's sponsorship of this large sub-study represents a major commitment of resources for our company. Our leadership in sponsoring this clinical study again reinforces Volcano's commitment to advancing the field of interventional cardiology and improving patient safety and care."

About Volcano Corporation

Volcano Corporation offers a broad suite of devices designed to facilitate endovascular procedures, enhance the diagnosis of vascular and structural heart diseases and guide optimal therapies. The company's intravascular ultrasound (IVUS) product line includes ultrasound consoles that can be integrated directly into virtually any modern cath lab and single-use phased array and rotational IVUS imaging catheters. Volcano also has unique advanced functionality options like VH(TM) IVUS tissue characterization and ChromaFlo(TM). Volcano also provides functional measurement (FM) consoles and single-use pressure and flow guide wires. Currently, more than 2,700 Volcano IVUS and FM systems are installed worldwide. For more information, visit the company's website at

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements involve risks and uncertainties and are based on management's current expectations. Actual results could differ materially from these forward-looking statements as a result of certain factors, including the risks and uncertainties related to the results of clinical studies and other factors discussed in Volcano's filings with the Securities and Exchange Commission. Undue reliance should not be placed on forward-looking statements, which speak only as of the time they are made. Volcano undertakes no obligation to update any forward-looking statements to reflect new information, events or circumstances, changed assumptions or otherwise. Actual results or experience could differ materially from the forward-looking statements.

* S.T.L.L.R stands for "The Impact of Stent Deployment Techniques on

Clinical Outcomes on Patients Treated with the Cypher(R) Stent." Dr.

Marco Costa was the lead investigator of this double-blinded clinical

study of almost 1,500 patients treated with the Johnson & Johnson /

Cordis drug-eluting CYPHER stent. The study was sponsored by Cordis,

and findings were presented at TCT in 2006.

SOURCE Volcano Corporation
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Pixantrone Combination Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Results in Reduction in Severe Toxicities Including Heart Damage When Compared to Doxorubicin-based Therapy
3. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
4. Ablynx Announces Interim Results of First Nanobody Phase I Study of ALX-0081 (ANTI-VWF)
5. Advanced Life Sciences Announces Supplemental Efficacy Data from First Pivotal Phase 3 Pneumonia Clinical Trial
6. Advanced Life Sciences to Host Conference Call to Discuss Data From Cethromycins First of Two Phase 3 Pneumonia Trials
7. First Phase II Short-Term Study on Dapagliflozin Shows Results on Safety, Tolerability and Glycemic Markers in Subjects With Type 2 Diabetes
8. Advanced Cell Technology Develops First Human Embryonic Stem Cell Line without Destroying an Embryo
9. First Demonstration of nanoImmunology: a Nanomaterials-based Therapeutic Approach to Treat Allergy
10. First single breast cancer study to show significant survival benefit for women switching from tamoxifen to Arimidex
11. Mymetics HIV Vaccine Demonstrates First-Ever Production of Neutralizing IgA Antibodies in Non-Human Primate Model
Post Your Comments:
(Date:11/26/2015)... DUBLIN , Nov. 26, 2015 Research and ... "Asia Pacific Cardiac Pacemaker Market Outlook to 2019 - ... Drive the Demand " report to their offering. ... --> Boston scientific and others. ... global players including Medtronic, Biotronik, Boston ...
(Date:11/26/2015)... DUBLIN , November 26, 2015 /PRNewswire/ ... the addition of the "2016 Future ... Drugs of Abuse Testing Market: Supplier Shares, ... report to their offering. --> ... of the "2016 Future Horizons and ...
(Date:11/26/2015)... , November 26, 2015 ... Juntendo universitetssjukhus ser potential att använda ... magnetresonansbilder (MR-bilder) för patienter med multipel ... ett forskningsavtal med SyntheticMR AB för att ... forskningsprojekt på sjukhuset. Med SyMRI kan man ...
Breaking Medicine Technology:
(Date:11/27/2015)... , ... November 27, 2015 , ... A team of ... ways to treat it. Surviving Mesothelioma has just posted the findings on the website. ... Hospital Zurich analyzed the cases of 136 mesothelioma patients who were treated with chemotherapy ...
(Date:11/27/2015)... ... 27, 2015 , ... ProSidebar: Fashion is a set of 30 ... ProSidebar: Fasion, video editors can easily add an informative sidebar to any FCPX production. ... Utilize presets featuring self-animating drop zones, lines, bars, and text with the ease of ...
(Date:11/27/2015)... ... 27, 2015 , ... The moment you stop improving is ... fulfilling the needs of advisers and clients but going above and beyond to ... customer service. However, there's always room for improvement, which is why the entire ...
(Date:11/27/2015)... ... 2015 , ... Avid collector, Andrew Hawley from Vintage Rock Posters, announces his ... is one of Joplin's most famous and beautiful concert posters. The concert was held ... Ann Arbor. The According to Hawley, "It is hard to believe that Joplin's stardom ...
(Date:11/26/2015)... ... November 26, 2015 , ... ... Travel Representative. As a franchise owner, Somu now offers travelers, value and care ... wedding packages, private cruise sales, as well as, cabin upgrades and special amenities ...
Breaking Medicine News(10 mins):